Two oral semaglutides — only one is a Bridge drug

Why people mix the bottles

Both are swallowed semaglutide from the same manufacturer family. Both use an empty-stomach style routine. That is where the resemblance should stop for coverage purposes.

Rybelsus is labeled for type 2 diabetes. Wegovy pill launched January 2026 as the oral Wegovy product. The pharmacy NDC and the indication on the Rx decide the claim type.

Bridge lists Wegovy pill. It does not list Rybelsus.

Demonstration drugs are Wegovy (pen and pill), Foundayo, and Zepbound KwikPen. A Rybelsus fill cannot be made into a $50 Bridge claim by renaming it at the counter.

If the person has type 2 diabetes, the correct instinct is Part D for the diabetes-labeled product the plan covers — not a demonstration obesity path.

Part D versus $50

A covered Rybelsus Part D claim usually counts toward deductible and TrOOP. Extra Help, if present, can apply. A Bridge Wegovy pill claim is $50 that does not count and does not take Extra Help.

Do not switch a working diabetes fill to Wegovy pill 'because Bridge is fifty dollars.' That can close Bridge (prior 2026 Part D GLP-1) and scramble the indication.

Routine is similar, labels are not copied

Expect empty stomach, limited water, and a wait before food or other orals on both inserts — and then read the insert you were dispensed. Fluid amounts and wait times are not something to borrow from a different brand name.

Cash

Wegovy pill cash: 4 mg $149 through 31 August 2026, then $199; maintenance often $299. Rybelsus cash, if offered, is a different list. Commercial cards are indication- and product-specific and exclude government coverage.